Navigation Links
BSP's New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study

BSP's HyperQ(TM) Monitoring System will Allow Bedside Detection of Ischemic

Events and Myocardial Infarction (Heart Attack)

TEL AVIV, Israel, February 26 /PRNewswire/ -- BSP (Biological Signal Processing Ltd.) an Israeli company which develops and markets systems for non-invasive diagnosis and monitoring of ischemic heart disease, announces successful results in detecting ischemic events using its proprietary HyperQ technology in resting conditions.

The successful results of the study indicate that the HyperQ(TM) technology, based on sophisticated analysis of high-frequency ECG components, can be implemented in two products: (i) bedside monitoring system for early detection of transient ischemic episodes and (ii) a resting ECG system for sensitive diagnosis of acute coronary syndrome, including myocardial infarction. A highly important clinical application of these two devices is the identification of heart attacks that are not accompanied by changes in standard ECG.

The results of the study showed that both HyperQ(TM) indices detected ischemia more accurately than ST analysis. Overall accuracy of HyperQ-based analysis was found to be 96% for the intensity-based index and 82% for the morphology-based index, both significantly higher than the accuracy of the conventional ST segment analysis at 75%.

"We are proud to present the first results that indicate clearly the HyperQ's strength in ischemia monitoring in a resting condition," said Dr. Amir Beker, Founder & CEO of BSP. "This carries an immense clinical value to cardiac patients, and marks the feasibility of BSP's next product line - the monitoring and resting HyperQ systems, which are planned to be offered to the market by early 2009. BSP will launch the commercial introduction of the HyperQ(TM) Stress System in the US at the 57th ACC Meeting this March." added Dr. Beker.

About BSP

BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP's HyperQ technology is implemented in cardiac systems that offer highly reliable, low-cost and risk free cardiac monitoring and allows, for the first time, an effective diagnosis of Ischemic Heart Diseases in broad populations. BSP's HyperQ(TM) System for Stress Tests has received FDA clearance and obtained CE marking.

BSP was founded in 2000 by Dr. Amir Beker, and Ariel Landau, had completed a successful IPO in mid-2006 and is traded on the Tel Aviv Stock Exchange.


Dr. Amir Beker,


SOURCE BSP - Biological Signal Processing Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
2. CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinsons Disease Motor Symptoms
3. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
9. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
10. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
Post Your Comments:
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
Breaking Biology News(10 mins):